Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 12 of 27
A Study of Lasmiditan in Healthy Participants
NCT03182920
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus
NCT03131687
A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis
NCT03129100
Absorption, Metabolism and Excretion of [14C]-Lasmiditan - Single Oral Dose Administration
NCT03040362
A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors
NCT03099109
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
NCT03073200
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
NCT03076970
A Study of LY3337641 in Japanese and Caucasian Healthy Participants
NCT03083561
Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function
NCT03040479
Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer
NCT02923921
A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease
NCT03019536
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
NCT02981342
A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
NCT02963766
A Study of Ixekizumab in Participants With Plaque Psoriasis
NCT02993471
A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease
NCT02891226
A Study of LY3323795 in Healthy Participants
NCT02989389
A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy
NCT02973100
A Study of LY3041658 in Participants With Skin Diseases
NCT02896868
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
NCT02784795
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
NCT02789345
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
NCT02745769
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
NCT02783599
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
NCT02857270
Biomarker Study in Participants With Migraine
NCT02766517
A Study of Single and Repeated Doses of LY3556050 in Healthy Participants
NCT05341102
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis
NCT02899988
A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants
NCT02917733
A Study of LY3337641 in Healthy Male Participants
NCT02914379
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
NCT02677116
A Study of LY3337641 in Rheumatoid Arthritis
NCT02628028
A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
NCT02860780
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
NCT02757352
A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants
NCT02884089
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
NCT02797951
A Study of Galcanezumab in Healthy Participants.
NCT02836613
A Study of LY3023414 Formulations and the Effect of Food
NCT02818335
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
NCT02791334
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
NCT02718911
A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia
NCT02791191
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
NCT02734160
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
NCT02760602
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
NCT02675231
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
NCT02735980
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
NCT02759107
A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis
NCT02696785
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
NCT02605174
A Study of Merestinib (LY2801653) in Healthy Participants
NCT02779738
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
NCT02754830
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis
NCT02696798
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis
NCT02718898
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.